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Abstract Biased agonism describes a multistate model of G
protein-coupled receptor activation in which each ligand in-
duces a unique structural conformation of the receptor, such
that the receptor couples differentially to G proteins and other
intracellular proteins. P2Y receptors are G protein-coupled
receptors that are activated by endogenous nucleotides, such
as adenosine 5′-triphosphate (ATP) and uridine 5′-triphos-
phate (UTP). A previous report suggested that UTP may be
a biased agonist at the human P2Y11 receptor, as it increased
cytosolic [Ca2+], but did not induce accumulation of inositol
phosphates, whereas ATP did both. The mechanism of action
of UTP was unclear, so the aim of this study was to charac-
terise the interaction of UTPwith the P2Y11 receptor in greater
detail. Intracellular Ca2+ was monitored in 1321N1 cells sta-
bly expressing human P2Y11 receptors using the Ca
2+-sensi-
tive fluorescent indicator, fluo-4. ATP evoked a rapid,
concentration-dependent rise in intracellular Ca2+, but surpris-
ingly, even high concentrations of UTP were ineffective. In
contrast, UTP was slightly, but significantly more potent than
ATP in evoking a rise in intracellular Ca2+ in 1321N1 cells
stably expressing the human P2Y2 receptor, with no difference
in the maximum response. Thus, the lack of response to UTP
at hP2Y11 receptors was not due to a problem with the UTP
solution. Furthermore, coapplying a high concentration of
UTP with ATP did not inhibit the response to ATP. Thus,
contrary to a previous report, we find no evidence for an
agonist action of UTP at the human P2Y11 receptor, nor does
UTP act as an antagonist.
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Abbreviations
1321N1-hP2Y2 cells 1321N1 cells stably expressing the
human P2Y2 receptor
1321N1-hP2Y11 cells 1321N1 cells stably expressing the
human P2Y11 receptor
95 % cl 95 % confidence limits
ATP Adenosine 5′-triphosphate




In the classical pharmacological model of drug-receptor inter-
action, all agonists at a G protein-coupled receptor (GPCR)
activate the same G protein(s) and signalling pathways, and
agonists differ only in their affinity for the receptor and
efficacy in stimulating the second messenger(s). It is now
clear, however, that receptors can in fact couple to different
G proteins and signalling pathways in an agonist-dependent
manner, a process termed biased agonism or functional selec-
tivity [1]. For example, coupling of the D2-dopamine receptor
to Gαi1, Gαi2, Gαi3 and Gαo1 varies with the agonist used [2]
and the relative efficacy of 5-HT2C agonists depends on
whether phospholipase C or A2 activity is measured [3].
Similar results have been reported for a variety of other
GPCR, including μ-opioid, adrenoceptors and vasopressin
receptors.
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These data suggest a multistate model of GPCR activation
in which each ligand induces a unique structural conformation
of the receptor that couples differentially to G proteins and
other proteins, such as arrestins, that interact with GPCR.
Direct evidence for this model was obtained recently by
imaging agonist-induced changes in the conformational struc-
ture of the β2-adrenoceptor [4] and arginine-vasopressin type
2 receptor [5]. In both studies, one group of agonists caused
the cytoplasmic end of helix VI of the receptor to move,
shifting the equilibrium towards G protein coupling, whilst
another group moved the cytoplasmic end of helix VII, lead-
ing to binding of β-arrestin to the receptor.
P2Y receptors are activated by endogenous nucleotides,
such as adenosine 5′-triphosphate (ATP) and uridine 5′-triphos-
phate (UTP) [6–8], but there are few reports of biased agonism.
ATP and UTP induce differential interaction of the human
P2Y2 receptor with β-arrestins and the downstream increase
in phosphorylation of ERK elicited by UTP was transient,
whereas the response to ATP was prolonged [9]. Intriguingly,
it has been reported that whilst ATP stimulation of the human
P2Y11 receptor caused accumulation of inositol phosphates
(IPs) and a rise in cytosolic [Ca2+], UTP had only the latter
effect [10]. Thus, ATP and UTP appear to interact with the
P2Y11 receptor to recruit distinct signalling pathways, but how
UTP produced its effects is unclear. Biased agonism has im-
portant implications for rational drug design as it raises the
possibility of developing new drugs that only activate a desired,
beneficial function of a GPCR, thus optimising their therapeutic
effect. The aim of this study was, therefore, to investigate the
mechanisms by which UTP increases cytosolic [Ca2+] and so
characterise biased agonism at P2Y11 receptors in greater detail.
Methods and materials
Culture of 1321N1 cells
1321N1 cells, a human astrocytoma cell line, stably express-
ing the human P2Y11 (1321N1-hP2Y11) [11] or P2Y2
(1321N1-hP2Y2) [12] receptors were maintained in 5 %
CO2, 95 % O2 in a humidified incubator at 37 °C, in
Dulbecco’s Modified Eagles Media (DMEM) supplemented
with 10 % foetal calf serum, 1 % nonessential amino acids,
1 % penicillin (10,000 units/ml) and streptomycin (10 mg/ml).
For recording intracellular Ca2+, the cells were plated onto 13-
mm glass coverslips coated with poly-L-lysine (0.1 mg/ml).
Experiments were performed once a confluent monolayer of
cells had developed.
Ca2+ imaging
Intracellular Ca2+ was monitored using the Ca2+-sensitive
fluorescent indicator, fluo-4. Cells on a coverslip were
incubated with fluo-4 AM ester (5 μM) at room temperature
in the dark for at least 1 h. The coverslip was then placed in the
recording chamber of a Perkin Elmer LS50B luminescence
spectrophotometer and the cells superfused continuously at
4 ml/min and room temperature with buffer composed of
(mM): NaCl 122; KCl 5; HEPES 10; KH2PO4 0.5; NaH2PO4
0.5; MgCl2 1; glucose 11; CaCl2 1.8, titrated to pH 7.3 with
NaOH. Fluo-4 fluorescence, measured as arbitrary units (AU),
in a population of cells was sampled at 10 Hz following
stimulation at 494±10 nm and the emission recorded at 516
±10 nm using FLWinlab software (V4.00.02). ATP and UTP
were added in the superfusate for 90–120 s at 10-min inter-
vals. Preliminary experiments showed that reproducible re-
sponses were evoked under these conditions. Unless indicated
otherwise, data were normalised by calculating the response in
AU as a percentage of the response to ATP (10 μM) (1321N1-
hP2Y11 cells) or ATP (1 μM) (1321N1-hP2Y2 cells).
IP formation
Generation of inositol phosphates (IPs) was measured as
described previously [11]. Briefly, 1321N1-hP2Y11 cells were
seeded in 24-well plates at 105 cells per well and assayed
3 days later when confluent. Inositol lipids were radiolabeled
by incubation of the cells for 24 h with 200 μl inositol-free,
serum-free DMEM high glucose and 0.4 μCi myo-[3-
H]inositol. No changes of medium were made subsequent to
the addition of [3H]inositol. Drugs were added in 50 μl of a
fivefold concentrated solution in 50 mM LiCl, 250 mM
HEPES, pH 7.4. Following a 5-min incubation at 37 °C, the
medium was aspirated and the assay terminated by adding
0.75 ml boiling 10 mM EDTA, pH 8.0. [3H]IPs were then
resolved by Dowex AG1-X8 columns [13].
Data analysis
Values in the text and figures refer to mean±S.E.M. or geo-
metric mean with 95 % confidence limits (95 % cl) for EC50
values. Data were compared by paired (Ca2+ imaging data)
and unpaired (IP data) t-tests as appropriate. Differences were
considered significant if P<0.05.
Drugs, solutions
ATP (disodium salt) and UTP (sodium salt) (Sigma/RBI, UK)
were dissolved in deionised water as 10 mM stock solutions
and diluted in buffer before use. Fluo-4 AM ester (Invitrogen,
UK) was dissolved in DMSO as a 1mM stock solution, frozen
immediately and stored at −20 °C. On the day of use, it was
diluted in buffer before use.
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Results
A previous study reported that ATP and UTP both increased
intracellular Ca2+ in 1321N1-hP2Y11 cells [10], so initial
experiments were carried out to confirm these data. Figure 1
shows that ATP (0.1–30 μM) evoked a rapid rise in intracel-
lular Ca2+ that was not maintained in the continued presence
of ATP. The response amplitude was concentration-
dependent, with an EC50=2.1 μM (95 % cl. 1.8––2.4 μM)
(n=5). Surprisingly, in the same cells, even high concentra-
tions of UTP (10 μM, n=6 and 100 μM, n=12) had no effect
on intracellular Ca2+ (Fig. 1).
To confirm that the UTP solution was active, we repeated
these experiments in 1321N1-hP2Y2 cells. Both nucleotides
evoked rapid, transient rises in intracellular Ca2+ in a
concentration-dependent manner, with EC50 values of 73
nM for UTP (95 % cl. 59–90 nM) and 176 nM for ATP
(95 % cl. 156–199 nM) (n=4 each) (Fig. 2). Indeed, UTP
was slightly, but significantly more potent than ATP
(P<0.01), but there was no difference in the maximum re-
sponse. The lack of response to UTP in 1321N1-hP2Y11 cells
was not, therefore, due to a problem with the UTP solution.
These data show that we could not confirm the previous
report [10] that UTP acts at the hP2Y11 receptor to raise
intracellular Ca2+. A possible explanation is that UTP did bind
to the receptor, but for an unknown reason, did not activate it.
To address this possibility, we determined if coadministration
of UTP inhibited the response to ATP. Control responses were
obtained to ATP (2 μM), a concentration close to its EC50.
Superfusing 1321N1-hP2Y11 cells with UTP (100 μM) for
10 min before reapplying ATP (2 μM) along with UTP
(100 μM) had no significant effect on the response to ATP
(Fig. 3a, b).
Previous studies on hP2Y11 receptors reported that ATP,
but not UTP, induced accumulation of IPs [14, 15], so we
determined if UTP could inhibit this action of ATP. UTP
(100 μM) alone did not alter basal level of IPs (not shown)
nor was the rise in IPs elicited by ATP (3 μM) significantly
affected by coadministration of UTP (100μM) (Fig. 3c). Thus
two bioassays of receptor activity show that UTP is also not an
antagonist at the human P2Y11 receptor.
Discussion
Biased agonism, a process in which agonists bind the same
receptor subtype, but activate different signalling pathways, is
an important discovery that has implications for rational drug
design, as it could lead to the development of new therapeutic
agents that selectively stimulate beneficial functions of a
GPCR. A previous study indicated that UTP is a biased agonist
at human P2Y11 receptors, inducing Ca
2+ mobilisation, so the
aim of this studywas characterise this action in detail.Wewere,
however, unable to replicate UTP agonism. Nucleotides can
also act as P2Y receptor antagonists [16], but even high con-
centrations of UTP did not inhibit ATP in two bioassays of
P2Y11 receptor activity, Ca
2+ mobilisation and accumulation of
IPs. Thus, we conclude that UTP is neither an agonist nor an
antagonist at the human P2Y11 receptor.
In this study, ATP evoked a rapid, concentration-dependent
rise in intracellular Ca2+ with an EC50 of 2.1 μM, which is
very close to the value of 2.7 μM seen in the earlier study that
suggested biased agonism at the P2Y11 receptor [10]. We
reported previously an EC50 of 8.1 μM for ATP-induced
accumulation of IPs in the same cells [11], which is similar
to the value of 12.6 μM reported in the earlier study [10] for
that response. Thus the potency of ATP seen in the two
laboratories was essentially the same, suggesting similar
levels of P2Y11 receptor expression. This is not surprising,
as the 1312N1-hP2Y11 cell line used in both studies was
generated by two of the present authors (CK, RAN) at the
University of North Carolina. Despite this, we did not observe
a rise in intracellular Ca2+ when UTP was applied, even at
Fig. 1 ATP, but not UTP, increases intracellular Ca2+ in 1321N1-hP2Y11
cells. a The superimposed traces show fluo-4 fluorescence during
superfusion with ATP (10 μM) (upper trace) and UTP (100 μM) (lower
trace) for 90 s, as indicated by horizontal bar. Both records are from the
same population of cells. b The mean peak amplitude of responses
evoked by ATP (n=5) and UTP (10 μM, n=6 and 100 μM, n=12) are
shown. Responses are expressed as percent of the response to ATP
(10 μM). Vertical lines show S.E.M
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100 μM, a concentration that was almost maximally effective
in the earlier study [10]. 1321 N1 cells are often used for
expression of recombinant P2Y receptors because they not
express any endogenous P2Y subtypes [6], and the earlier
study [10] confirmed the absence of mRNA for the UTP-
sensitive P2Y2 and P2Y4 receptors in the 1321N1-hP2Y11
cells, eliminating those subtypes as the site of action of UTP.
Thus it is unlikely that the inactivity of UTP in our study was
due to differences in the expression of P2Y receptors.
Several other possible explanations for the difference in the
responsiveness to UTP can be considered. Contamination by
hydrolysis products of UTP is unlikely to be the cause of the
discrepancy as the previous study monitored UTP purity by
HPLC and eliminated its initial breakdown product, uridine
5′-diphosphate, using a creatine phosphokinase regenerating
system. In contrast, the UTP solution used in the present study
was ≥80 % pure, with ≤15 % UDP and ≤5 % UMP, so if
hydrolysis products of UTP were to induce a Ca2+ response, it
would most likely have been seen in our study. Differences in
the composition of the extracellular buffer are also unlikely to
be an explanation, as in both studies, the 1321N1-hP2Y11 cells
were superfused with a Krebs-HEPES buffer containing
10 mM HEPES. Although White et al., [10] gave no further
details of the buffer composition, any differences in the ions
Fig. 2 ATP and UTP increase intracellular Ca2+ in 1321N1-hP2Y2 cells.
a The trace shows fluo-4 fluorescence during superfusion with UTP
(1 μM) for 90 s, as indicated by horizontal bar. b The mean peak
amplitude of responses evoked by ATP (n=4) and UTP (n=4), expressed
as percent of the response to ATP (1 μM). Vertical lines show S.E.M
Fig. 3 UTP does not inhibit ATP-evoked responses in 1321N1-hP2Y11
cells. a The traces show the rise in intracellular Ca2+ evoked by ATP
(2 μM) in the same population of cells before (left-hand side) and after
superfusion for 10 min with UTP (100 μM) (right-hand side), as indicat-
ed by the horizontal bars. b The mean peak amplitude of responses
evoked by ATP (2 μM) in the absence and presence of UTP (100 μM,
n=5) are shown. Responses are expressed as percent of the control
response to ATP (2 μM). c The mean basal level of IPs (left-hand
column) and the mean amplitude of responses evoked by ATP (3 μM)
in the absence (middle column) and presence of UTP (100 μM) (right-
hand column) are shown. n=3. Vertical lines indicate S.E.M
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present would have to substantial in order to produce such a
large difference in the responsiveness to UTP. Consequently,
the most feasible explanation in our view is contamination of
the UTP solution by a non-nucleotide agent acting at a recep-
tor that is not a P2Y receptor.
In conclusion, we have demonstrated that ATP acts at the
human P2Y11 receptor to initiate a rise in cytoplasmic Ca
2+,
but this response is neither mimicked nor inhibited by high
concentrations of UTP. Thus, contrary to a previous report, we
have found no evidence that UTP is a biased agonist at the
human P2Y11 receptor.
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